CRISPR Therapeutics AG
CRSP43.205USD
+1.625+3.91%
Horário de mercado （ET）Cotações atrasadas em 15 min
3.73BValor de mercado
PerdaP/L TTM
Mais detalhes de CRISPR Therapeutics AG Empresa
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.
Informações da empresa
Código da empresaCRSP
Nome da EmpresaCRISPR Therapeutics AG
Data de listagemOct 19, 2016
Fundado em2013
CEODr. Samarth Kulkarni, Ph.D.
Número de funcionários393
Tipo de títulosOrdinary Share
Fim do ano fiscalOct 19
EndereçoBaarerstrasse 14
CidadeZUG
Bolsa de valoresNASDAQ Global Market Consolidated
PaísSwitzerland
Código postal6300
Telefone41415613279
Sitehttps://crisprtx.com/
Código da empresaCRSP
Data de listagemOct 19, 2016
Fundado em2013
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
280.71K
+18.70%
Dr. Raju Prasad, Ph.D.
Dr. Raju Prasad, Ph.D.
Chief Financial Officer
Chief Financial Officer
13.01K
+30.05%
Mr. John Thomas Greene
Mr. John Thomas Greene
Independent Director
Independent Director
7.00K
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
270.00
--
Mr. James R. Kasinger, J.D.
Mr. James R. Kasinger, J.D.
General Counsel, Secretary
General Counsel, Secretary
--
--
Dr. Naimish Patel, M.D.
Dr. Naimish Patel, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Sandesh Mahatme
Mr. Sandesh Mahatme
Independent Director
Independent Director
--
--
Dr. Katherine A. High, M.D.
Dr. Katherine A. High, M.D.
Independent Director
Independent Director
--
--
Dr. Maria Fardis, Ph.D.
Dr. Maria Fardis, Ph.D.
Independent Director
Independent Director
--
--
Dr. H. Edward Fleming, Jr., M.D.
Dr. H. Edward Fleming, Jr., M.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
280.71K
+18.70%
Dr. Raju Prasad, Ph.D.
Dr. Raju Prasad, Ph.D.
Chief Financial Officer
Chief Financial Officer
13.01K
+30.05%
Mr. John Thomas Greene
Mr. John Thomas Greene
Independent Director
Independent Director
7.00K
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
270.00
--
Mr. James R. Kasinger, J.D.
Mr. James R. Kasinger, J.D.
General Counsel, Secretary
General Counsel, Secretary
--
--
Dr. Naimish Patel, M.D.
Dr. Naimish Patel, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: ter, 20 de mai
Atualizado em: ter, 20 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
ARK Investment Management LLC
11.77%
Capital International Investors
7.03%
T. Rowe Price Investment Management, Inc.
4.40%
Nikko Asset Management Co., Ltd.
2.94%
Nikko Asset Management Americas, Inc.
2.94%
Other
70.92%
Investidores
Investidores
Proporção
ARK Investment Management LLC
11.77%
Capital International Investors
7.03%
T. Rowe Price Investment Management, Inc.
4.40%
Nikko Asset Management Co., Ltd.
2.94%
Nikko Asset Management Americas, Inc.
2.94%
Other
70.92%
Tipos de investidores
Investidores
Proporção
Investment Advisor
41.25%
Investment Advisor/Hedge Fund
20.51%
Hedge Fund
5.55%
Research Firm
4.15%
Venture Capital
3.64%
Individual Investor
1.69%
Bank and Trust
0.73%
Sovereign Wealth Fund
0.51%
Pension Fund
0.39%
Other
21.57%
Participação acionária institucional
Atualizado em: seg, 24 de fev
Atualizado em: seg, 24 de fev
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q1
934
69.16M
80.09%
-72.64K
2024Q4
955
68.20M
79.52%
-1.17M
2024Q3
962
64.14M
75.29%
-1.47M
2024Q2
976
63.22M
74.44%
-1.89M
2024Q1
986
62.72M
74.09%
+4.47M
2023Q4
985
55.14M
69.41%
-4.96M
2023Q3
992
55.19M
69.50%
-6.68M
2023Q2
1037
54.86M
69.51%
-8.28M
2023Q1
1053
55.90M
70.89%
-6.49M
2022Q4
1074
54.64M
69.81%
-8.49M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
ARK Investment Management LLC
8.97M
10.46%
-149.43K
-1.64%
Dec 31, 2024
Capital International Investors
8.74M
10.19%
+816.79K
+10.30%
Dec 31, 2024
T. Rowe Price Investment Management, Inc.
3.81M
4.44%
+1.07M
+39.24%
Dec 31, 2024
Nikko Asset Management Co., Ltd.
2.75M
3.2%
-222.36K
-7.49%
Dec 31, 2024
Nikko Asset Management Americas, Inc.
2.75M
3.2%
-221.54K
-7.47%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
2.51M
2.93%
+87.43K
+3.60%
Dec 31, 2024
State Street Global Advisors (US)
2.49M
2.9%
-501.46K
-16.75%
Dec 31, 2024
Fidelity Management & Research Company LLC
2.22M
2.59%
-152.87K
-6.43%
Dec 31, 2024
The Vanguard Group, Inc.
1.72M
2%
+8.83K
+0.52%
Dec 31, 2024
Ver Mais
ETFs Relacionados
Atualizado em: sex, 6 de jun
Atualizado em: sex, 6 de jun
Nome
Proporção
ARK Genomic Revolution ETF
7.73%
ARK Innovation ETF
5.02%
Global X Genomics & Biotechnology ETF
3.5%
AXS Green Alpha ETF
3.22%
WisdomTree BioRevolution Fund
1.95%
Virtus LifeSci Biotech Products ETF
1.39%
SPDR S&P Biotech ETF
1.19%
Direxion Daily S&P Biotech Bull 3X Shares
0.78%
Main Thematic Innovation ETF
0.56%
Invesco Nasdaq Biotechnology ETF
0.33%
Ver Mais
ARK Genomic Revolution ETF
Proporção7.73%
ARK Innovation ETF
Proporção5.02%
Global X Genomics & Biotechnology ETF
Proporção3.5%
AXS Green Alpha ETF
Proporção3.22%
WisdomTree BioRevolution Fund
Proporção1.95%
Virtus LifeSci Biotech Products ETF
Proporção1.39%
SPDR S&P Biotech ETF
Proporção1.19%
Direxion Daily S&P Biotech Bull 3X Shares
Proporção0.78%
Main Thematic Innovation ETF
Proporção0.56%
Invesco Nasdaq Biotechnology ETF
Proporção0.33%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
